Intraocular Pressure-Lowering Efficacy of Brinzolamide 1%/Timolol 0.5% Fixed Combination Compared with Brinzolamide 1% and Timolol 0.5%
| Autor: | Martin, Kaback, Stephen V, Scoper, George, Arzeno, John E, James, Steven Y, Hua, Craig, Salem, Jaime E, Dickerson, Theresa A, Landry, Michael V W, Bergamini, Thomas R, Walters |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Intraocular pressure genetic structures Adrenergic beta-Antagonists Brinzolamide Thiazines Visual Acuity Timolol Ocular hypertension Glaucoma law.invention Tonometry Ocular Double-Blind Method Randomized controlled trial law Humans Medicine Prospective Studies Carbonic Anhydrase Inhibitors Adverse effect Prospective cohort study Intraocular Pressure Aged Aged 80 and over Sulfonamides business.industry Middle Aged medicine.disease eye diseases Drug Combinations Ophthalmology Anesthesia Female Ocular Hypertension sense organs business Glaucoma Open-Angle medicine.drug |
| Zdroj: | Ophthalmology. 115:1728-1734.e2 |
| ISSN: | 0161-6420 |
| DOI: | 10.1016/j.ophtha.2008.04.011 |
| Popis: | Purpose To compare the safety and intraocular pressure (IOP)-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination with brinzolamide 1% or timolol 0.5% alone in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Design Randomized, double-masked, parallel group, multicenter study. Participants Five hundred twenty-three patients were randomized to the study treatments. Methods Patients with OAG or OHT were recruited to the study. Qualifying eyes had IOPs of 24 to 36 mmHg at 8 am and 21 to 36 mmHg at 10 am on 2 eligibility visits after an appropriate washout period from previous treatment. Patients were assigned randomly to either brinzolamide 1%/timolol 0.5%, brinzolamide 1% (Azopt; Alcon Laboratories, Fort Worth, TX), or timolol 0.5%, dosed twice daily and were followed up while receiving therapy for 6 months. At selected sites, additional IOP measurements were performed at 12 pm , 4 pm , and 8 pm during the 2 eligibility visits, at month 3, and at month 6. Main Outcome Measure Mean IOP. Results Brinzolamide 1%/timolol 0.5% produced statistically significant and clinically relevant reductions from baseline ranging from 8.0 to 8.7 mmHg, which were statistically and clinically superior to that of either brinzolamide 1% (5.1–5.6 mmHg) or timolol 0.5% (5.7–6.9 mmHg). No safety concerns were identified based on an assessment of ocular and cardiovascular parameters and a review of adverse events. Conclusions Brinzolamide 1%/timolol 05% is superior in IOP-lowering efficacy to either brinzolamide 1% or timolol 0.5%. Financial Disclosure(s) Proprietary or commercial disclosure may be found after the references. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|